Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | TTK | P33981 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2060016 | 0.86 | GRM5 (0.41) | GRM5KDRMCHR1SMYD3 | |
| SCHEMBL2060039 | 0.79 | KDR (0.55) | GRM5KDRTTKARSMYD3 | |
| SCHEMBL2060136 | 0.79 | MCHR1 (0.46) | GRM5MCHR1HTR1AADRA2AADRA1A | |
| SCHEMBL2060124 | 0.74 | RIPK1 (0.47) | GRM5KDRMCHR1HTR1AADRA2A | |
| SCHEMBL2060043 | 0.71 | RIPK1 (0.52) | GRM5MCHR1HTR1AADRA2AADRA1A | |
| SCHEMBL885593 | 0.69 | MCHR1 (0.45) | GRM5MCHR1HTR1AADRA2AADRA1A | |
| SCHEMBL885700 | 0.68 | RIPK1 (0.53) | GRM5MCHR1HTR1AADRA2AADRA1A | |
| SCHEMBL885847 | 0.68 | RIPK1 (0.48) | GRM5MCHR1SMYD3 | |
| SCHEMBL25678076 | 0.66 | GRM5 (0.58) | GRM5KDR | |
| SCHEMBL2060020 | 0.66 | KDR (0.47) | GRM5KDRSMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081928-B1 | Pyrrolo-pyridine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| CN-101600714-B | Novel pyrindole kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2013-08-21 | — | — | CN | disclosed |
| US-8148361-B2 | Kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100041636-A1 | NOVEL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| CN-101600714-A | Novel kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-12-09 | — | — | CN | disclosed |
| EP-2081928-A2 | PYRROLO-PYRIDINE KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008060907-A2 | PYRROLO-PYRIDINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041636-A1 | NOVEL KINASE INHIBITORS | IGF1R, FGFR1, FLT1 | GRM5 2155/4885KDR 5/4885TTK 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.